Design Therapeutics (DSGN) Share-based Compensation (2020 - 2026)

Design Therapeutics (DSGN) has 7 years of Share-based Compensation data on file, last reported at $3.9 million in Q1 2026.

• For the quarter ending Q1 2026, Share-based Compensation rose 10.88% year-over-year to $3.9 million; the trailing twelve-month figure through Mar 2026 stood at $14.9 million (up 11.22% YoY), and the FY2025 full-year result was $20.7 million, up 21.05% from the prior year.
• Share-based Compensation rose to $3.9 million in Q1 2026, from $3.4 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $4.0 million in Q2 2025 to a low of $2.4 million in Q1 2022.
• A 5-year average of $3.3 million and a median of $3.3 million in 2024 frame the typical range for Share-based Compensation.
• Across the five-year window, Share-based Compensation jumped 264.76% in 2022 and declined 11.44% in 2023, its largest moves.
• Tracing DSGN's Share-based Compensation over 5 years: stood at $3.1 million in 2022, then retreated by 11.44% to $2.7 million in 2023, then rose by 27.42% to $3.5 million in 2024, then dropped by 1.04% to $3.4 million in 2025, then gained by 14.24% to $3.9 million in 2026.
• Business Quant data shows DSGN's Share-based Compensation at $3.9 million in Q1 2026, $3.4 million in Q4 2025, and $3.6 million in Q3 2025.